Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Danyelza Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The Danyelza market has shown significant growth, driven by developments in pediatric oncology. Advances in monoclonal antibody therapy, pediatric oncology specialization, and the clinical success of GD2 targeting have been pivotal. The forecast period indicates further growth facilitated by pediatric cancer trials, expansion of immuno-oncology pipelines, and increased access to specialty cancer centers. Notable trends involve the adoption of targeted immunotherapy and increased use of GD2-directed treatments for refractory and relapsed cancers.
The rising incidence of pediatric cancers, including leukemia, brain tumors, neuroblastoma, and lymphomas, is a key driver for the Danyelza market. Factors such as advancements in diagnostic methods and genetic predispositions contribute to this increasing prevalence. Danyelza (naxitamab), a targeted immunotherapy, has been effective in treating high-risk neuroblastoma alongside other therapies, improving survival rates and reducing disease progression. Recent statistics highlight the challenges and demand for effective treatments, as seen in Australia's pediatric cancer cases, underscoring the significance of Danyelza's role.
Leading companies in the Danyelza market, such as Y-mAbs Therapeutics Inc., are prioritizing the development of innovative targeted immunotherapies. These treatments effectively target cancer cells by leveraging specific markers like GD2. In 2023, Y-mAbs received marketing authorization from Brazil for Danyelza, emphasizing its global impact and utility.
Strategic partnerships, such as the one between Nobelpharma Co., Ltd. and Y-mAbs Therapeutics Inc., are expanding Danyelza's reach, enabling development, regulatory submission, and marketing in Japan. This collaboration underscores the importance of international cooperation in addressing pediatric oncology needs.
North America currently leads the Danyelza market, with significant developments and market shares spread across regions like Asia-Pacific and Europe. The market report provides insights into regional dynamics and identifies opportunities for growth and expansion globally.
Tariffs have notably influenced the market by affecting biologic manufacturing inputs and logistics, mostly impacting regions like Asia-Pacific. However, these challenges have fostered regional manufacturing partnerships that enhance long-term access to pediatric oncology therapies.
The comprehensive Danyelza market research report covers global market size, trends, opportunities, and detailed analysis necessary for navigating the industry's present and future landscape. The market includes sales of genetically modified donor pancreas cells, cell transplantation, and immune suppression drugs, reflecting its extensive scope and impact.
Danyelza, identified as a monoclonal antibody combined with granulocyte-macrophage colony-stimulating factor, is primarily approved for patients 1 year and older with high-risk neuroblastoma. It targets GD2 proteins on cancer cells, enhancing the immune system's ability to combat these malignancies.
The market primarily targets neuroblastoma, osteosarcoma, and other GD2-positive cancers, with treatment distribution through hospitals, specialty clinics, and cancer centers. The market values reflect revenues sourced from global sales and services offered by the manufacturers.
Report Scope:
- Markets Covered:
- Indication: Neuroblastoma; Osteosarcoma and other GD2-positive cancers
- Treatment Type: Monotherapy; Combination Therapy
- End User: Hospitals; Specialty Clinics; Cancer and Radiation Therapy Centers.
- Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa.
- Time Series: Five years historic and ten years forecast.
- Data: Market size and growth ratios relative to connected markets, GDP shares, expenditure per capita.
- Data Segmentation: Historical and forecast data segmented by country and region, competitive market share analysis, market segmentations.
Key Topics Covered:
1. Executive Summary
1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market
2. Danyelza Market Characteristics
2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Danyelza Market Attractiveness Scoring and Analysis
3. Danyelza Market Supply Chain Analysis
3.1. Overview of the Supply Chain and Ecosystem
3.2. List of Key Raw Materials, Resources & Suppliers
3.3. List of Major Distributors and Channel Partners
3.4. List of Major End Users
4. Global Danyelza Market Trends and Strategies
4.1. Key Technologies & Future Trends
4.2. Major Trends
5. Danyelza Market Analysis of End Use Industries
5.1 Hospitals
5.2 Pediatric Oncology Centers
5.3 Specialty Cancer Clinics
5.4 Academic Medical Centers
5.5 Radiation Therapy Centers
6. Danyelza Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, and Covid and Recovery on the Market
7. Global Danyelza Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
7.1. Global Danyelza PESTEL Analysis
7.2. Global Danyelza Market Size, Comparisons and Growth Rate Analysis
7.3. Global Danyelza Historic Market Size and Growth, 2020-2025, Value ($ Billion)
7.4. Global Danyelza Forecast Market Size and Growth, 2025-2030, 2035F, Value ($ Billion)
8. Global Danyelza Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Danyelza Market Segmentation
9.1. Global Danyelza Market, Segmentation by Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.2. Global Danyelza Market, Segmentation by Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.3. Global Danyelza Market, Segmentation by End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/sihsao
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
